Stonegate Investment Group LLC Acquires 3,824 Shares of AstraZeneca PLC (NASDAQ:AZN)

Stonegate Investment Group LLC grew its holdings in shares of AstraZeneca PLC (NASDAQ:AZNFree Report) by 40.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,222 shares of the company’s stock after buying an additional 3,824 shares during the quarter. Stonegate Investment Group LLC’s holdings in AstraZeneca were worth $891,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Wellington Management Group LLP increased its holdings in AstraZeneca by 0.7% during the third quarter. Wellington Management Group LLP now owns 49,492,814 shares of the company’s stock worth $3,351,653,000 after buying an additional 358,399 shares during the last quarter. Jennison Associates LLC grew its position in shares of AstraZeneca by 5.2% in the 3rd quarter. Jennison Associates LLC now owns 22,946,504 shares of the company’s stock valued at $1,553,937,000 after acquiring an additional 1,139,295 shares during the period. Sanders Capital LLC acquired a new position in shares of AstraZeneca during the 3rd quarter worth about $715,198,000. Morgan Stanley raised its holdings in shares of AstraZeneca by 18.0% in the 4th quarter. Morgan Stanley now owns 10,222,597 shares of the company’s stock valued at $693,092,000 after purchasing an additional 1,561,194 shares during the period. Finally, BlackRock Inc. lifted its stake in AstraZeneca by 22.0% in the 1st quarter. BlackRock Inc. now owns 7,466,492 shares of the company’s stock valued at $495,328,000 after purchasing an additional 1,343,939 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on AZN. Jefferies Financial Group downgraded AstraZeneca from a “buy” rating to a “hold” rating in a research report on Wednesday, January 3rd. HSBC initiated coverage on AstraZeneca in a research note on Monday, December 18th. They issued a “buy” rating on the stock. Morgan Stanley started coverage on shares of AstraZeneca in a research report on Tuesday, January 23rd. They set an “overweight” rating for the company. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of AstraZeneca from a “hold” rating to a “sell” rating in a report on Thursday, February 8th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $80.00.

Check Out Our Latest Analysis on AZN

AstraZeneca Price Performance

Shares of NASDAQ AZN opened at $67.00 on Wednesday. The firm has a market cap of $207.73 billion, a P/E ratio of 34.90, a price-to-earnings-growth ratio of 1.24 and a beta of 0.50. The business’s 50 day moving average is $65.69 and its 200-day moving average is $65.80. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.57. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $76.56.

AstraZeneca (NASDAQ:AZNGet Free Report) last posted its quarterly earnings data on Thursday, February 8th. The company reported $0.73 earnings per share for the quarter, missing the consensus estimate of $0.74 by ($0.01). AstraZeneca had a return on equity of 30.19% and a net margin of 13.00%. The firm had revenue of $12.02 billion for the quarter, compared to the consensus estimate of $12.07 billion. During the same quarter in the previous year, the business earned $0.69 EPS. The firm’s quarterly revenue was up 7.3% on a year-over-year basis. Equities research analysts predict that AstraZeneca PLC will post 4.01 earnings per share for the current year.

AstraZeneca Increases Dividend

The firm also recently disclosed a Semi-Annual dividend, which was paid on Monday, March 25th. Shareholders of record on Friday, February 23rd were paid a $0.965 dividend. This is a boost from AstraZeneca’s previous Semi-Annual dividend of $0.47. The ex-dividend date of this dividend was Thursday, February 22nd. This represents a yield of 2.3%. AstraZeneca’s payout ratio is 100.52%.

AstraZeneca Profile

(Free Report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

Featured Articles

Institutional Ownership by Quarter for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.